Huiyue Medical Completes Tens of Millions RMB Angel Financing to Accelerate Integrated Diagnosis and Treatment Solutions for the Entire Digestive Tract

VCBeat has exclusively learned that recently, a surgical robot positioned for intelligent natural orifice surgerySuzhou Huiyue Medical Technology Co., Ltd. (hereinafter referred to as “Huiyue Medical”), announced the completion ofTusPark VenturesLed a tens-of-millions-yuan angel round of financing, which will be used for the company's product type testing and clinical trials.Sun Capital PartnersServed as the exclusive financial advisor for this round of financing.

Huiyue Medical was established in 2022 in Suzhou Industrial Park, specializing in the research and development, manufacturing, and sales of AI-powered surgical robots. The company’s core technologies are derived from scientific and technological achievements under the National Key R&D Program, and all key components of its products are independently developed.

The team at Huiyue Medical largely comprises graduates from prestigious universities such as Harbin Institute of Technology, Shanghai Jiao Tong University, Dalian University of Technology, and Northeastern University, with professional backgrounds spanning electrical engineering, mechanical engineering, software engineering, biomedical engineering, and other fields. Notably, over 80% of the staff hold master’s or doctoral degrees. Furthermore, the company has established an expert workstation, inviting professors from top-tier universities and Grade A tertiary hospitals to serve as technical consultants.

With the widespread application of laparoscopic surgical robots in minimally invasive surgery, their technology has gradually expanded into the field of flexible endoscopic procedures, such as digestive endoscopy. A growing body of research indicates that surgical robots can enhance the operational efficiency and safety of flexible endoscopic surgeries, while shortening the learning curve.

Digestive endoscopy is highly technique-dependent for physicians, lacks sufficient intelligence, and suffers from inadequate standardization. Challenges include the significant distance between the control and execution ends, substantial loss of operational force during transmission, and the need to balance force and flexibility within narrow, tortuous lumens. Leveraging robotics and AI-based imaging technologies can address these difficulties and reduce risks. This represents a transformation of traditional surgical paradigms, enabling physicians to rapidly progress from novices to independent operators, thereby holding significant clinical importance and market potential.

After years of breakthroughs in key technologies, Huiyue Medical has launched an intelligent digestive endoscopic surgical robot with independent intellectual property rights. This product adopts internationally pioneering innovative technology with independent intellectual property rights and is a platform-based digestive endoscopic surgical robot that integrates diagnosis and treatment.

This robot features three core functions:

• Intelligent Gastrointestinal Endoscopy Examination.Endoscopic procedures demand high technical proficiency, involve a large patient population, entail significant labor intensity, and often lack standardization, making them prone to missed or incorrect diagnoses. This function integrates artificial intelligence recognition technology with robotics to achieve standardized operations, improve the detection rate of early-stage cancers and other diseases, and prevent diagnostic errors. Furthermore, it facilitates tiered diagnosis and treatment in primary care hospitals through remote assisted diagnostic capabilities.

• Endoscopic Submucosal Dissection (ESD) for Early-Stage Tumors.Currently, endoscopic electrosurgical dissection is associated with operational difficulties and a high risk of bleeding and perforation. This feature employs flexible and intelligent control to fully expose the surgical field, accurately reach the lesion site for precise resection, effectively reduce the risks of bleeding and perforation, and make the procedure simpler and more effective.

• Intelligent Interventional Therapy for Biliary and Pancreatic Ducts (ERCP).ERCP procedures are associated with high risks, significant technical difficulty, severe potential complications, and a prolonged training period, typically requiring three to five years. This feature effectively addresses the challenge of cannulation in ERCP, substantially improving procedural success rates and reducing the risk of complications. It also significantly shortens the physician training curve, enabling clinicians to perform the procedure after only a few training sessions. Furthermore, it helps prevent radiation exposure hazards for physicians.

Huiyue Medical’s intelligent digestive endoscopic surgical robot has pioneered the integration of diagnosis and treatment across the entire gastrointestinal tract, providing comprehensive coverage for gastrointestinal diseases. It not only shortens physicians’ learning curves and reduces variability in surgical proficiency, but also helps more doctors rapidly master endoscopic submucosal dissection (ESD) and endoscopic retrograde cholangiopancreatography (ERCP) procedures, thereby enhancing surgical safety and efficiency. Preliminary clinical validation has been conducted for certain features of its product series.

Huiyue Medical has also demonstrated exceptional strength in intellectual property, holding full independent IP rights for all its core products and having filed dozens of patents. The company has established close clinical collaborations with multiple top-tier teaching hospitals in China, positioning itself as one of the most advanced technology firms in the country with the most comprehensive product portfolio and leading technologies in the fields of natural orifice precision diagnostics and minimally invasive interventional therapy.

Furthermore,Huiyue Medical was also honored with the title of “Leading Talent Enterprise” in Suzhou Industrial Park and won the Excellence Award at the HICOOL Global Entrepreneurship and Innovation Competition in September 2024.

Regarding the acquisition of this round of financing,Liu Bo, Founder and CEO of Huiyue MedicalStatement: We extend our sincere gratitude to TusPark Ventures for its trust in Huiyue Medical, and we also thank Sunstone Capital for its full cooperation. The company boasts a world-class robotics R&D team and a global business perspective. With years of deep engagement in the healthcare industry, we have brought together a group of like-minded partners to strive together. Amidst the opportunities and challenges characterizing the global healthcare sector, we remain true to our original aspiration. Guided by the mission to “make no surgery difficult,” we are committed to addressing genuine clinical pain points by starting from patient needs. We adhere to independent original research and development, focus on R&D that targets market pain points, and involve sales and marketing teams in product development. This approach achieves a deep integration of robotic technology, healthcare industry needs, and business models, forming a tripartite operational model. Through this, we aim to advance medical technology and contribute value to the cause of human health.

Liu Huiqin, Managing Director of TusPark VenturesTusPark Ventures is honored to have assisted Huiyue Medical in completing this round of financing. Huiyue Medical’s flagship product, the intelligent digestive endoscopic surgical robot, is a globally leading, cutting-edge innovation. Its design closely addresses critical clinical pain points, offering substantial market potential. Furthermore, the founding team adopts a “scientist + industry expert” model, bringing profound technical expertise, deep medical insights, and extensive market experience in the field of surgical robotics. The R&D team demonstrates strong capabilities, high execution efficiency, and solid technical accumulation, with proven experience in developing medical robotic products and excellent scalability. Moreover, Huiyue Medical has demonstrated visionary strategic planning and a clear, smooth commercialization pathway. We believe that with the support of additional prominent shareholders, Huiyue Medical will further accelerate its pace in pioneering a new era for surgical robots.

Ji Guoming, Founder of SunStone CapitalStatement: Sun Star Capital is honored to have assisted Huiyue Medical in completing this round of financing and will continue to provide the company with comprehensive, in-depth capital services. As a global pioneer in gastrointestinal surgical robotics, Huiyue Medical offers an integrated solution for gastrointestinal diagnosis and treatment. Its intelligent gastroscopy and colonoscopy capabilities enable standardized procedures, help prevent missed or misdiagnoses, provide a basis for early diagnosis and treatment, and facilitate remote medical consultations. Ms. Liu Bo, the company’s CEO, has a clinical professional background and has dedicated nearly 20 years to the field of minimally invasive endoscopy and consumables. She possesses extensive knowledge of the industry landscape and the potential market for related products, along with a profound understanding of the core competitiveness and market translation of products in this sector. Previously, she was responsible for the marketing and sales of products such as Olympus and ERBE in multiple provinces across China. All core components of the company’s products are independently developed, ensuring strong potential for future performance iterations and significant room for cost optimization. We believe that with financial support, Huiyue Medical’s products will enter clinical application more quickly and earlier, ultimately benefiting society as a whole.

TusPark Ventures was restructured and established in 2014 against the strategic backdrop of promoting the commercialization of scientific and technological achievements at Tsinghua University. It is a professional investment management firm primarily focused on early-stage investments in technology-driven innovative enterprises. TusPark Ventures concentrates on key sectors such as life sciences, medical devices, information technology, and advanced manufacturing. The firm has long been dedicated to investing in innovative companies with core hard technologies, while distinguishing itself through its specialized focus on incubating and investing in scientific and technological achievements derived from clinical experts at universities and top-tier hospitals.

TusPark Ventures currently manages funds totaling over RMB 3 billion and has invested in more than 80 projects. Two-thirds of these portfolio companies hold dominant positions in their respective niche markets, while more than half feature technologies that are first-of-their-kind in China or even globally. The firm has delivered strong financial returns to its investors and has been included on the white list of “Class A Private Equity Fund Managers for Insurance Capital Investment” published by the Insurance Asset Management Association of China.

Sun Star Capital’s core business focus is to accelerate the growth of high-potential technology enterprises, committed to long-term value investing and in-depth services, with the mission of leveraging technology for the betterment of humanity. The founding team has over a decade of experience in the investment industry and has invested in more than 20 industry-leading companies in sectors such as healthcare, scientific research, and enterprise services, serving as a key partner in their growth journeys.

Drawing on in-depth research into the management of tech startup lifecycles, macroeconomic development trends, and decades of hands-on equity practice in the frontline of technology enterprises, the company provides strategic, talent, capital, and managerial support to accelerate rapid business growth. Going forward, the company will focus primarily on healthcare, scientific research, and intelligent manufacturing.